Bioventus (NASDAQ:BVS) Earns “Outperform” Rating from Barrington Research

Bioventus (NASDAQ:BVS)‘s stock had its “outperform” rating reiterated by equities researchers at Barrington Research in a research note issued on Tuesday,Benzinga reports. They currently have a $14.00 price target on the stock. Barrington Research’s price objective would indicate a potential upside of 43.15% from the stock’s previous close.

Several other equities research analysts have also recently commented on the stock. CJS Securities assumed coverage on shares of Bioventus in a research report on Friday, March 27th. They issued a “market outperform” rating and a $14.00 target price for the company. Cantor Fitzgerald upgraded shares of Bioventus to a “strong-buy” rating in a research report on Wednesday, March 4th. Craig Hallum increased their price target on shares of Bioventus from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. Weiss Ratings restated a “hold (c)” rating on shares of Bioventus in a report on Tuesday, June 2nd. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $15.00 price objective on shares of Bioventus in a report on Tuesday, June 16th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $14.20.

Bioventus Price Performance

Shares of BVS stock opened at $9.78 on Tuesday. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.13 and a current ratio of 1.69. Bioventus has a fifty-two week low of $5.81 and a fifty-two week high of $11.25. The firm has a market cap of $817.02 million, a P/E ratio of 23.85, a P/E/G ratio of 1.26 and a beta of 0.67. The business’s 50 day moving average price is $9.53 and its 200-day moving average price is $8.76.

Bioventus (NASDAQ:BVS) last announced its earnings results on Wednesday, May 6th. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.06. The company had revenue of $132.09 million during the quarter. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, equities research analysts anticipate that Bioventus will post 0.77 earnings per share for the current year.

Institutional Investors Weigh In On Bioventus

Hedge funds have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd increased its holdings in shares of Bioventus by 17,156.2% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock valued at $41,000 after acquiring an additional 5,490 shares in the last quarter. Prelude Capital Management LLC bought a new position in Bioventus in the 3rd quarter worth about $74,000. Mercer Global Advisors Inc. ADV purchased a new stake in Bioventus during the 3rd quarter valued at about $78,000. SG Americas Securities LLC purchased a new stake in Bioventus during the 4th quarter valued at about $80,000. Finally, Brooklyn Investment Group bought a new position in shares of Bioventus in the fourth quarter worth approximately $91,000. 62.94% of the stock is owned by institutional investors.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.